Press Releases
InspireMD Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015
BOSTON, MA – March 28, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced its financial and operating results for the fourth quarter and year ended December 31, 2015. In 2015, InspireMD advanced its strategic transition into the… Read More
InspireMD Announces Closing of Public Offering
BOSTON, MA – March 21, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced the closing of an underwritten public offering of 1,900,000 shares of its common stock and warrants to purchase up to 950,000 shares of common stock (the “Public Offering”). The common stock was sold… Read More
InspireMD Announces Closing of Private Placement to Certain Officers and Directors
BOSTON, MA – March 21, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced the closing of its private placement of 1,033,051 shares of its common stock and warrants to purchase up to 516,526 shares of common stock to certain of the Company’s officers and directors (the… Read More
InspireMD Announces Pricing of Public Offering
BOSTON, MA – March 16, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced the pricing of an underwritten public offering of 1,900,000 shares of its common stock and warrants to purchase up to 950,000 shares of common stock (the “Public Offering”). The common… Read More
InspireMD Announces Private Placement to Certain Officers and Directors
BOSTON, MA – March 16, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced a private placement (the “Private Placement”) of up to 1,100,000 shares of its common stock and warrants to purchase up to 550,000 shares of common stock to certain of the… Read More
InspireMD Announces Proposed Public Offering of Common Stock and Warrants
BOSTON, MA – March 15, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase common stock. Dawson James Securities, Inc., is serving as the sole… Read More
InspireMD Aligns Operations and Leadership Team, Appoints Isaac Blech as Vice Chairman of the Board
Enhances Commercial and Development Execution Reduces Operating Cost Structure Strengthens Board of Directors BOSTON, MA – January 22, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today plans to align its operations and leadership with focus on… Read More
InspireMD Receives EU Regulatory Approval for Additional Supplier of CGuardTM Delivery Catheters
BOSTON, MA – December 2, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today receipt of a DEKRA medical device certification for the manufacture and commercialization of its CGuardTM delivery catheter, which now incorporates some design enhancements and… Read More
InspireMD Announces Positive Twelve Month Follow-Up CARENET Trial Data at VEITH Symposium 2015
 BOSTON, MA – November 20, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today positive 12 month follow up data from its CGuardTM CARENET (CARotid Embolic protection Study using microNET) trial at the 42nd Annual Symposium on Vascular… Read More
InspireMD Reports Financial Results for the Third Quarter Ended September 30, 2015
BOSTON, MA – November 10, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced its financial and operating results for the third quarter ended September 30, 2015. In its third full quarter of a strategic transition into the… Read More